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Abstract
Objective: To investigate the combined effect of both pioglitazone and methotrexate on disease activity of rheumatoid arthritis in a 
biphasic study; experimental and clinical.
Methods: Experimentally: 50 rats were divided into 5 equal groups; controls, experimental arthritis, methorexate treated (0.1 mg/Kg 
daily), pioglitazone-treated (10 mg/kg daily), and methotrexate and pioglitazone treated. Clinically: forty-nine diabetic rheumatoid 
arthritis patients were included. Patients group consisted of 28 patients and they received pioglitazone 30 mg orally beside their usual 
treatment. Control group consisted of 21 patients and they continued their usual treatment plus placebo. Disease activity was assessed 
using DAS28 score. Patients were followed up for 3 months.
Results: Pioglitazone produced a significant improvement of serum oxidative stress parameters (P , 0.05), and inflammatory cytokines 
in  the  treated  arthritic  group  (P  ,  0.05).  Clinically,  the  pioglitazone  treated  group  showed  significant  improvement  in  DAS28   
(P = 0.001) and C-reactive protein (P , 0.0001) compared to placebo group.
Conclusion: The concomitant use of the PPAR γ agonist pioglitazone and methotrexate appears to be promising therapeutic strategy for 
rheumatoid arthritis patients.
Keywords: pioglitazone, PPAR-γ agonist, anti-inflammatory, oxidative stress, rheumatoid arthritis, disease activityShahin et al
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Introduction
Rheumatoid arthritis (RA) is an autoimmune systemic 
inflammatory disease. Recent studies have found that 
there  is  increased  prevalence  of  coronary  artery 
atherosclerosis1,2  metabolic  syndrome3  and  insulin 
resistance4 among RA patients. Furthermore, hyper-
insulinemia has been associated with disease activity,4 
suggesting that inflammation and hyperinsulinemia 
somehow interact and facilitate one another.
Pioglitazone  is  a  member  of  oral  antidiabetic 
agents, the thiazolidinediones (TZDs). TZDs have 
been proven to improve insulin resistance, reduce 
circulating hyper-insulinemia and master the regula-
tion  of  adipogenesis  and  glucose  metabolism.5,6 
They act as ligands for the peroxisome proliferator-
activated receptor gamma (PPAR-γ), a member of 
the nuclear hormone receptor superfamily of tran-
scription factors. PPAR-γ is expressed in a broad 
array of human tissues,5 Recently, PPAR-γ has been 
suggested to be an important immunomodulator; it 
suppresses  the  production  of  inflammatory 
cytokines7,8  matrix  metalloproteinases,9  reactive 
oxygen species10 and inhibits pro-inflammatory gene 
expression.11  Furthermore,  PPAR-γ  ligands  have 
been shown to induce apoptosis in T lymphocytes,12,13 
and macrophages.14
Since the potential anti-inflammatory properties of 
PPAR-γ ligands on RA activity have been investi-
gated in several experimental arthritis models, this 
study was conducted to evaluate the effect of PPAR-γ 
agonist  pioglitazone  combined  with  methotrexate 
(MTX) in RA either experimentally or clinically in 
RA diabetic patients.
Methods
experimental study
Drugs used
Methotrexate (Ebewe Co, Austria, ampoule 50 mg/5 ml) 
and Pioglitazone hydrochloride (Amoun Co, Egypt, tab 
30 mg dissolved in 0.5% sodium carboxy methyl cel-
lulose for oral administration).
Animals used
This study was carried on 50 male Sprague-Dawley rats 
weighing 200–250 gm/rat. Animals had free access to 
food and water. They were exposed to the same housing 
conditions of heat and humidity. Animals were handled 
with the Guide for Care and Use of Laboratory Animals 
as adopted by the National Institutes of Health.
Animal grouping
Rats were divided into 5 equal groups (10 rats for 
each). Group 1 Control group: rats received 0.5% 
sodium carboxy methyl cellulose; Group 2 Control 
group:  Non-treated  arthritic  group,  arthritic  rats 
received  0.5%  sodium    carboxy  methyl  cellulose; 
Group 3 Control group: MTX treated arthritic group, 
arthritic rats received MTX 0.1 mg/Kg/d;16 Group 4 
Control group: Pioglitazone treated arthritic group, 
arthritic  rats  received  pioglitazone  10  mg/kg/d;17 
Group  5  Control  group:  MTX  and  Pioglitazone 
treated arthritic group, arthritic rats received MTX 
and Pioglitazone by the same previous doses. Ani-
mals were treated with drugs every 24 h, starting 
from day 28 orally via gastric tube for 16 days.
Induction of collagen- induced arthritis (CIA)
Collagen-induced arthritis was induced as previously 
described by Billingham.15 Bovine type II collagen 
(CII) was dissolved in 0.01 M acetic acid at a concen-
tration of 2 mg ml−1 by stirring overnight at 4 °C. Dis-
solved CII was frozen at −70 °C until use. Complete 
Freund’s adjuvant (CFA) was prepared by the addi-
tion of Mycobacterium tuberculosis H37Ra at a con-
centration of 2 mg/ml (Difco, Laboratories, Detroit, 
  Michigan). Before injection, CII was emulsified with 
an equal volume of CFA by centrifugation at 300 r.p.m. 
for  5  minutes  (Virtis  23  homogenizer,  Gardmer, 
New York). On day 1, rats were injected intradermally 
at the base of the tail with 100 µl of the emulsion 
(containing 100 µg of CII). On day 21, a second injec-
tion of CII in CFA was administered. Animals were 
received drugs every 24 h, starting from day 28, orally 
via gastric tube for 16 days.
Arthritic score of CIA
Arthritis was monitored every 4 days by using a mac-
roscopic scoring system ranging from 0 to 4 for each 
limb, as previously described by Bakharevski et al,18 as 
follows. 0, no arthritis; 1, swelling and/or redness of 
one to two interphalangeal (IP) joints; 2, involvement 
of three to four IP joints or one larger joint; 3, more 
than four joints red/swollen; 4, severe arthritis of an 
entire paw, yielding a score of 0 to 16 per animal.Pioglitazone and methotrexate in rheumatoid arthritis
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Biochemical Analyses
After the end of treatment, all rats were sacrified by an 
overdose of anesthesia. Trunk blood of each rat was 
collected and allowed to clot and centrifuged at 7000 
r.p.m. for 15 minutes. The serum samples were sepa-
rated carefully and stored at −30 °C until the biochemi-
cal assay.
Quantitative determination of serum IL-1β using 
ELISA  kit  (Biosource  International,  Inc,  USA).19 
Serum  TNF-α  was  performed  by  TNF-α  ELISA 
kit (Ray Biotech, Inc, USA).20 Serum thiobarbituric 
acid  reactive  substance  (TBARS)  was  performed 
using Malondialdehyde Assay kit Northwest, Life Sci-
ence  Specialities,  (NWLSS,  Canada).21 Serum total 
glutathione (GSH) was performed using ELISA kit 
(Cayman Chemical Company, USA).22 Serum super-
oxide dismutase activity (SOD) was performed using 
an ELISA kit (Cayman Chemical Company, USA).23
The absorbance of each sample was read on plate 
ELISA reader.
clinical study
Patients and methods
Inclusion criteria
Forty-nine rheumatoid arthritis (RA) patients with dia-
betes mellitus type II, attending the Rheumatology and 
Immunology outpatient clinic in Mansoura   University 
Hospital, Egypt between January 2009 and March 2010 
were included in the study. The diagnosis of RA was 
confirmed by a rheumatologist according to the Ameri-
can College of Rheumatology (ACR) 1987 criteria for 
RA.24 Disease activity was assessed by calculating the 
disease activity for 28 joint indices (DAS28). Online 
calculator is available at www.das-score.nl.
exclusion criteria
Pregnant and lactating subjects and patients with his-
tory of heart failure, renal failure, active liver disease 
or elevated aminotransferases greater than twice the 
upper limit of normal or with known contraindication 
to pioglitazone were excluded from the study. Patients 
aged ,18 years was not eligible for the current study.
Study design
The  present  study  is  a  prospective,  single  blind, 
  therapeutic clinical trial. Eligible participants were 
RA  and  diabetic  patients.  They  were  subdivided 
into  two  groups.  The  patients  group,    consisting 
of  the    clinically  more  active  (having  2  of  the 
  following: .6 swollen joints, .6 tender joints, morn-
ing stiffness .one hour) RA patients (n = 28). They 
received pioglitazone 30 mg orally, once daily for 
12 weeks in addition to their treatment. The control 
group consisted of the remaining 21 patients who con-
tinued their treatment plus placebo orally, once daily 
for 12 weeks. The treatment of rheumatoid arthritis 
should be stable for at least three months before study 
entry and should include methotrexate orally 15 mg/
week plus non steroidal anti-inflammatory and/or oral 
corticosteroids #7.5 mg/day orally.
All participants underwent two study visits at 0 
and 12 weeks for assessment of disease activity, blood 
sampling, urine pregnancy test and response to therapy. 
Fasting blood samples were drawn for complete blood 
count (CBC), erythrocyte sedimentation rate (ESR), 
C- reactive protein (CRP), liver aminotransferases, 
and serum creatinine. All subjects also had non study 
visits at 4, and 8 week for regular follow up and occur-
rence of side effects.
All subjects gave their informed consent and the 
study  was  approved  by  the  Ethical  Committee  of 
Mansoura School of Medicine.
Statistical analysis
Data  were  analyzed  using  the  statistical  package 
SPSS version 17.0. Experimental data were expressed 
as means ± standard error (SE). Group differences 
were compared by using ANOVA followed by Tukey 
test. While clinical data were expressed as means ± 
standard deviation (SD) and group differences were 
compared by using t-test. Probability levels ,0.05 
were considered significant.
Results
results of the experimental study
characteristics of CIA in rats
There was no macroscopic evidence of either paw ery-
thema or edema in the normal control rats. As shown 
in Figure 1, animals subjected to CIA showed that the 
paw erythema and swelling increased in frequency 
and severity in a time-dependent mode with maximum 
arthritis indices of approximately 11 observed between 
40 to 44 days post-CII immunization. Either MTX, 
pioglitazone or their combination exerted a significant Shahin et al
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suppression (P1 , 0.001) of the arthritis index between 
days 32 and 44 post-CII immunization versus that of 
non-treated arthritic rats. There were non-significant 
changes between the combination-treated and the sin-
gle drug-treated arthritic groups.
Serum oxidative stress parameters
The serum level of oxidative stress parameters were 
compared  to  the  non-arthritic  group.  The  lipid 
peroxidation product TRBS was significantly increased 
(19.14 ± 0.87 versus 8.17 ± 0.41 µ mol/L, P1 = 0.001). 
Meanwhile the antioxidant markers were significantly 
decreased;  serum  GSH  (6.58  ±  0.33  versus 
11.32  ±  0.13  µ  mol,  P  =  0.001)  and  serum  SOD 
(0.138 ± 0.01 versus 0.376 ± 0.02 U/ml, P = 0.001).
Either MTX or pioglitazone treatment produced 
significant decrease of serum TBARS (14.22 ± 1.2 and 
14.95  ±  0.97  µ  mol/L,  P  =  0.001)  and  significant 
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Figure 1. effect of methotrexate (0.1 mg/kg) and pioglitazone (30 mg/kg) combination on the arthritic index of CIA rats. 
notes: Values are expressed as mean ± SeM. *P , 0.001 versus non-tretaed CIA group; rats number = 10.Pioglitazone and methotrexate in rheumatoid arthritis
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increase of both serum GSH (8.90 ± 0.68, P = 0.008 
and 7.20 ± 0.59 µ mol, P = 0.001) and serum SOD 
(0.256 ± 0.01, P = 0.001 and 0.227 ± 0.02 U/ml, 
P = 0.012) as compared to the non-treated arthritic 
group.
MTX and pioglitazone combination produced sig-
nificant  decrease  of  serum  TBARS  (9.23  ±  0.62  µ 
mol/L,  P , 0.05 and significant increase of both 
serum GSH (10.97 ± 0.76 µ mol, P , 0.05) and 
serum SOD (0.396 ± 0.02 U/ml, P , 0.05) as com-
pared to the non-treated, and/or pioglitazone treated 
arthritic groups (Table 1).
Serum inflammatory mediators
The serum level of the inflammatory mediator, TNF-α 
was significantly increased in the non treated CIA rats 
as  compared  to  the  non-arthritic  group  (178.77  ± 
14.79 versus 21.71 ± 1.90 pg/ml, P = 0.001). Also, 
IL-1β, was significantly increased in CIA rats versus 
the non-arthritic group (24.21 ± 2.39 versus 6.46 ± 
0.58 pg/ml, P = 0.001).
Either MTX or pioglitazone treatment resulted in 
significant  reduction  of  serum  level  of  TNF-α 
(45.64 ± 4.05 and 92.79 ± 8.06 pg/ml respectively, 
P = 0.001) and IL1β (12.33 ± 1.42 and 15.43 ± 1.39 
pg/ml respectively, P = 0.001) in comparison to that 
of the non-treated arthritic group. It was also noticed 
that MTX caused significant decrease in both TNF-α 
(P = 0.001) and IL1β (P = 0.04) as compared to pio-
glitazone treatment of the arthritic group.
Further, MTX and pioglitazone combination pro-
duced significant improvement of both serum level of 
TNF-α  (36.44  ±  2.53  pg/ml,  P  ,  0.05)  and  IL1β 
(10.00 ± 0.90 pg/ml, P , 0.05) in comparison to the 
non-treated  and  pioglitazone  treated  arthritic  group 
(Table 2). There was a non-significant change between 
the combination and MTX treated arthritic groups.
Results of the clinical study
The  pioglitazone  treated  group  of  patient  showed 
marked  improvement  as  regard  the  swollen  joint 
count (SJC), tender joint count (TJC), ESR, CRP, 
DAS (P , 0.0001). This was also associated with 
significant  reduction  of  blood  glucose  levels. 
(Table 3).
Table 1. effect of methotrexate (0.1 mg/kg) and pioglita-
zone  (30  mg/kg)  combination  on  the  serum  oxidative 
stress   parameters; TBArS, gSh, SOD, in CIA rats.
TBARs  
μ mol/L
GsH  
μ mol
sOD  
U/mL
non-arthritic  
group
8.17 ± 0.41 11.32 ± 0.13 0.376 ± 0.02
non-treated  
CIA group
19.14 ± 0.87 
P1 = 0.001
6.58 ± 0.33 
P1 = 0.001
0.138 ± 0.01 
P1 = 0.001
MTX treated  
CIA group
14.22 ± 1.20 
P1 = 0.001 
P2 = 0.001
8.90 ± 0.68 
P1 = 0.001 
P2 = 0.008
0.256 ± 0.01 
P1 = 0.001 
P2 = 0.001
Pioglitazone  
treated 
CIA group
14.95 ± 0.97 
P1 = 0.001 
P2 = 0.001
7.20 ± 0.59 
P1 = 0.03 
P2 = 0.001
0.227 ± 0.02 
P1 = 0.001 
P2 = 0.012
MTX +  
Pioglitazone 
treated  
CIA group
9.23 ± 0.62 
P1 = 0.04 
P2 = 0.001 
P3 = 0.001 
P4 = 0.001
10.97 ± 0.76 
P1 = NS 
P2 = 0.001 
P3 = 0.45 
P4 = 0.001
0.396 ± 0.02 
P1 = NS 
P2 = 0.001 
P3 = 0.001 
P4 = 0.001
notes: Values are expressed as mean ± SeM. P , 0.05 was significant. 
rats number = 10; P1 versus non-arthritic group; P2 versus non-treated 
CIA group; P3 versus MTX treated CIA group; P4 versus Pioglitazone 
treated CIA group.
Abbreviations: TBArS,  thiobarbituric  acid  reactive  substance;  gSh, 
glutathione; SOD, superoxide dismutase activity; CIA, collagen induced 
arthritis; MTX, methotrexate.
Table 2. effect of methotrexate (0.1 mg/kg) and pioglita-
zone (30 mg/kg) combination on the serum TnF-α, IL-1β 
in CIA rats.
TnF-α 
pg/mL
IL-1β 
pg/mL
non-arthritic  
group
21.71 ± 1.90 6.46 ± 0.58
non-treated  
CIA group
178.77 ± 14.79 
P1 = 0.001
24.21 ± 2.39 
P1 = 0.001
MTX treated  
CIA group
45.64 ± 4.05 
P1 = 0.001 
P2 = 0.001
12.33 ± 1.42 
P1 = 0.001 
P2 = 0.001
Pioglitazone  
treated group
92.79 ± 8.06 
P1 = 0.001 
P2 = 0.001 
P3 = 0.001
15.43 ± 1.39 
P1 = 0.001 
P2 = 0.001 
P3 = 0.04
MTX + Pioglitazone  
treated CIA group
36.44 ± 2.53 
P1 = 0.018 
P2 = 0.001 
P4 = 0.001
10.00 ± 0.90 
P1 = 0.015 
P2 = 0.001 
P4 = 0.001
notes: Values are expressed as mean ± SeM. P , 0.05 was significant. 
rats number = 10; P1 versus non-arthritic group; P2 versus non-treated 
CIA group; P3 versus MTX treated CIA group; P4 versus Pioglitazone 
treated CIA group.
Abbreviations: CIA, collagen induced arthritis; MTX, methotrexate; TnF, 
tumour necrosis factor; IL, interleukin.Shahin et al
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On  the  other  hand,  the  placebo  treated 
(pioglitazone non treated) group of patients showed 
significant improvement of DAS, TJC, ESR, CRP. 
However, there were no significant improvement of 
SJC nor the blood glucose levels (Table 4).
When comparing the pioglitazone treated group of 
patients with the placebo treated group before treat-
ment, it was found that there were significant differ-
ences as regard ESR, DAS28 score indicating that 
pioglitazone treated patients had more active disease 
(Table 5).
After 3 months, there were significant reductions 
of  DAS28  and  CRP  in  patients  assigned  for 
pioglitazone treatment compared to the other group 
of patients (P = 0.001 and P , 0.0001 respectively). 
Notably,  there  were  no  significant  differences  in 
blood  glucose  levels  between  the  two  groups 
(Table 6).
Seven (25%) out of the 28 patients who received 
pioglitazone in the current study reported weight 
gain. The increase in weight ranged from 2–4 kg. 
No other adverse effects were observed.
Table 3. Clinical and laboratorial characteristics of piogli-
tazone and methotrexate treated group of patients before 
and after treatment by pioglitazone (n = 28).
Before After P
SJC 4.7 ± 1 2.7 ± 0.7 ,0.0001
TJC 6 ± 1.2 3.1 ± 1.7 ,0.0001
eSr (mm/h) 49.9 ± 11.9 31.4 ± 7.4 ,0.0001
DAS28 5.2 ± 0.5 3.8 ± 0.4 ,0.0001
CrP (µg/mL) 20.4 ± 4.7 8.1 ± 3.1 ,0.0001
Fasting serum 
glucose (mg/dL)
219.6 ± 57 163.1 ± 28.1 ,0.0001
Post prandial 
serum  
glucose (mg/dL)
297.1 ± 120.3 217 ± 59.8 0.003
note: P significant at level ,0.05.
Abbreviations: SJC, swollen joint count; TJC, tender joint count; eSr, 
erythrocyte sedimentation rate; DAS28, disease activity score for 28 joint 
indices; CrP, C- reactive protein.
Table 4. Clinical and laboratorial characteristics of placebo 
and  methotrexate  treated  group  of  patients  before  and 
after treatment (n = 21).
Before After P
SJC 4.1 ± 2.5 3.1 ± 1.9 ns
TJC 5.6 ± 2.2 3.6 ± 1.3 0.001
eSr (mm/h) 32.1 ± 8.4 21.7 ± 3.5 ,0.0001
DAS28 4.6 ± 0.5 4.2 ± 0.5 0.025
CrP (µg/mL) 18.7 ± 5.2 13.6 ± 3.8 0.001
Fasting serum 
glucose (mg/dL)
174.4 ± 36.4 163.6 ± 28.8 ns
Post prandial 
serum  
glucose (mg/dL)
276.7 ± 113.3 245.7 ± 48.1 ns
note: P significant at level ,0.05.
Abbreviations:  ns,  non  significant;  SJC,  swollen  joint  count;  TJC, 
tender joint count; eSr, erythrocyte sedimentation rate; DAS28, disease 
activity score for 28 joint indices; CrP, C- reactive protein.
Table 5. Clinical and laboratorial characteristics of pioglita-
zone treated and non treated groups of patients* before 
treatment by pioglitazone and placebo.
pioglitazone 
treated group
pioglitazone  
non treated  
group
P
Age 43.4 ± 6.8 44.1 ± 7.1 ns
SJC 4.7 ± 1 4.1 ± 2.5 ns
TJC 6 ± 1.2 5.6 ± 2.2 ns
eSr (mm/h) 49.9 ± 11.9 32.1 ± 8.4 ,0.0001
DAS28 5.2 ± 0.5 4.6 ± 0.5 ,0.0001
CrP (µg/mL) 20.4 ± 4.7 18.7 ± 5.2 ns
Fasting serum 
glucose (mg/dL)
219.6 ± 57 174.4 ± 36.4 003
Post prandial 
serum  
glucose (mg/dL)
297.1 ± 120.3 276.7 ± 113.3 ns
note: P significant at level ,0.05. *all patients received 15 mg methot-
rexate orally once weekly.
Abbreviations: ns, non significant; SJC, swollen joint count; TJC, tender 
joint count; eSr, erythrocyte sedimentation rate; DAS28, disease activity 
score for 28 joint indices; CrP, C- reactive protein.
Table 6. Clinical and laboratorial characteristics of piogli-
tazone treated and non treated groups of patients* after 
treatment by pioglitazone and placebo.
pioglitazone 
treated  
group
pioglitazone  
non treated  
group
P
SJC 2.7 ± 0.7 3.1 ± 1.9 ns
TJC 3.1 ± 1.7 3.6 ± 1.3 ns
eSr (mm/h) 31.4 ± 7.4 21.7 ± 3.5 ,0.0001
DAS28 3.8 ± 0.4 4.2 ± 0.5 0.001
CrP (µg/mL) 8.1 ± 3.1 13.6 ± 3.8 ,0.0001
Fasting serum 
glucose (mg/dL)
163.1 ± 28.1 163.6 ± 28.8 ns
Post prandial 
serum  
glucose (mg/dL)
217.1 ± 59.8 245.7 ± 48.1 ns
note: P significant at level ,0.05. *all patients received 15 mg metho-
trexate orally once weekly.
Abbreviations:  ns,  non  significant;  SJC,  swollen  joint  count;  TJC, 
tender joint count; eSr, erythrocyte sedimentation rate; DAS28, disease 
activity score for 28 joint indices; CrP, C- reactive protein.Pioglitazone and methotrexate in rheumatoid arthritis
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Discussion
RA is a chronic, systemic inflammatory disease that is 
characterized by progressive joint destruction. Treatment 
of rheumatoid arthritis is a major health   problem. The 
available  disease  modifying  antirheumatic  drugs 
(DMARDs) and the recent biologics have promising 
protecting  effects  progressive  joint  destruction.25,26   
The clinical use of these therapies has been limited 
however due to several issues including safety and 
cost treatment.
In  this  study  the  lipid  peroxidation  products, 
TBARS was significantly elevated in the serum of 
CIA rats. Identification of TBARS in the serum has 
been recognized as indirect evidence of the effect 
of free radicals as mediators of tissue damage and 
inflammatory arthropathy in the pathogenesis of 
RA.27 ROS generated by phagocytes in the inflamed 
rheumatoid joint are not efficiently scavenged result-
ing in increased levels of lipid peroxidation prod-
ucts both in the synovial fluid and blood as a result of 
transportation by the circulatory system.28
The excessive state of oxidative stress in CIA rats, 
as evidenced by increased TBARS was associated 
with impaired antioxidant status components (GSH 
level and SOD activity) as compared to the control 
group. This is in agreement with Hassan et al29 who 
showed  that  RA  was  associated  with  significant 
depletion in GSH levels supporting a hypothesis that 
defense  mechanisms  against  ROS  are  impaired  in 
RA.  In  inflammatory  arthritis,  polymorphonuclear 
leukocytes and macrophages are responsible for this 
impaired antioxidant status.30,31
The present results showed that MTX treatment 
caused significant improvement of the arthritis index 
as well as modulation of the alterated parameters pro-
duced in CIA rats with respect to serum lipid peroxi-
dation, anti-oxidants levels, serum TNF-α and IL1β 
as compared to the CIA group. This can be attributed 
to its established antiinflammatory, anti-proliferative, 
immunosuppressive effects on activated T lympho-
cytes,  increasing  the  rate  of  apoptosis  of  T  cells, 
increasing endogenous adenosine release, altering the 
expression of cellular adhesion molecules, influencing 
production of cytokines, humoral responses and bone 
formation.4,32,33
In this study, it has been demonstrated that piogli-
tazone  produced  a  significant  improvement  of  the 
arthritis index that was associated with a significant 
reduction of the oxidative stress markers and the serum 
cytokines  (TNF-α  and  IL1β)  as  compared  to  CIA 
group.
MTX and pioglitazone combination also exerted a 
significant improvement of the arthritis index and sig-
nificant reduction of the oxidative stress markers and 
the serum cytokines (TNF-α and IL1β) as compared 
to the non-treated CIA group.
Tomita and associates34 observed that oral admin-
istration of PPAR-γ agonist resulted in reduced con-
centrations of proinflammatory cytokines at both the 
local  and  systemic  levels.  PPAR-γ  agonist  also 
decreased the expression of IL-1β and TNF-α  in 
arthritic synovium in joints of mice with established 
collagen-induced  arthritis.  In  support  of  this  pro-
posal the finding of Koufany et al35 that the TZDs 
(rosiglitazone 10 mg/kg/day or pioglitazone 30 mg/
kg/day)  decreased  the  expression  of  IL-1β  and 
TNF-α in inflamed synovium, which is a primary 
source  for  systemic  inflammatory  cytokines. This 
could be due to the ability of PPAR-γ agonists to 
inhibit IL-1β induced nitric oxide synthase expres-
sion  and  synthesis  in  chondrocytes  from  patients 
with  osteoarthritis.  PPAR-γ  ligands  also  inhibited 
IL-1β  induced    metalloproteinase-13  (MMP-13) 
expression and production in chondrocytes. In addi-
tion to IL-1β, other cytokines produced in arthritic 
joint tissues, such as IL-17 and TNF-α, may contrib-
ute to joint destruction through production of nitric 
oxide  (NO)  and  MMP-13.  As  expected,  PPAR-γ 
activators  inhibited  the  production  of  NO  and 
MMP-13 in response to TNF-α, IL-17, suggesting 
that  PPAR-γ  activators  may  target  common  path-
ways leading to NO and MMP-13 production.8 Fur-
ther, PPAR-γ activator inhibits IL-1β induced COX-2 
expression and PGE2 production by human chondro-
cytes  and  synovial  fibroblasts.36  A  high  level  of 
COX-2 induced prostaglandins is known to be asso-
ciated  with  the  oxidative  stress  as  COX-2  over 
expression induces the generation of free radicals 
and  lipid  peroxide  formations.37  Consequently, 
modulation of COX-2 by PPAR-γ agonist is another 
mechanism of the anti-  inflammatory, antioxidative 
effect of pioglitazone. Moreover, the anti-arthritic 
potency of PPAR-γ agonists may be due to their 
ability to inhibit the NF κB pathway in arthritic tis-
sues.38  Also,  TZDs  decreased  the  expression  of 
basic fibroblast growth factor (bFGF), which is a Shahin et al
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powerful mitogen for both synovial fibroblasts and 
endothelial cells whose neutralization was reported 
to attenuate arthritis severity.39
To the best of our knowledge, this is the first clinical 
study evaluating the effects of a PPAR-γ agonist (pio-
glitazone) combined with MTX as therapy for rheuma-
toid arthritis. In the present study, the group of patients 
treated with pioglitazone exhibited significant improve-
ment either clinically or in the laboratory. Also, there 
were significant reductions in the ESR, CRP and DAS28 
compared to the placebo treated group of patients. Of 
note, there was no difference in the blood glucose level 
between the two groups at the end of the study, indicat-
ing that the improvement in disease activity indices 
and markers is not due to the antibiabetic effect of pio-
glitazone. These results could be explained by the 
suggested  anti-inflammatory  effects  of  PPAR-γ 
ligands.40 Recent studies have indicated that many of 
the  cells  involved  with  RA,  namely  mononuclear 
leukocytes,41  articular  cartilage  and  chondrocytes42 
express PPAR-γ receptors.
In the experimental phase of the study, we have 
highlighted  the  participation  of  cytokines  in  the 
inflammation, even in the early phases of induced 
arthritis. It was reported that PPAR-γ agonists can 
inhibit the expression of adhesion molecules,43 the 
release of TNFα from the cultered RA synovial mem-
brane cells and spleen cells.34,44
Thus, there are several potential mechanisms by 
which  PPAR-γ  agonists  could  exert  their  anti- 
inflammatory effect.
Lately, the PPAR-γ agonists are emerging poten-
tial  therapies  for  inflammatory  cardiovascular 
diseases,11  psoriatic  arthritis,45  multiple  sclerosis,40 
chronic obstructive pulmonary disease46 and glomeru-
losclerosis.47 The findings in the present study suggest 
that PPAR-γ agonist (pioglitazone) could be a poten-
tial therapeutic agent for RA.
conclusion
In  conclusion,  this  study  demonstrated  that  the 
  concomitant use of MTX and pioglitazone may cause 
a synergistic effect in rheumatoid arthritis. We specu-
lated  that  the  observed  beneficial  effects  of  both   
drugs may be dependent upon a combination of the   
following pharmacological actions; 1) They inhibit 
inflammatory  cytokines  TNF-α,  IL-1β.  2)  They 
appear to   prevent the activation of ROS, ultimately 
the degree of tissue injury. The antioxidant and the 
anti-  inflammatory effects of pioglitazone and MTX 
support  the  possibility  that  patients  with  RA  may   
benefit from therapy with both of the above in combi-
nation.
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